Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825354 | Clinical Therapeutics | 2014 | 22 Pages |
Abstract
Larger SBP reductions were found to be cost-effective in both a 10-year and lifetime horizon. These findings might call for more aggressive SBP reductions in patients with mild hypertension. However, a high level of uncertainty surrounds these cost-effectiveness estimates because they are based on CVD risk prediction modeling.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jelena MSc, Anouk C. MSc, Bram G. MSc, Nynke PhD, Maarten J. PhD, Petros PhD,